THAY ĐỔI GIÁ TRỊ qHBsAg Ở BỆNH NHÂN VIÊM GAN VI RÚT B MẠN KHI ĐIỀU TRỊ BẰNG TENOFOVIR DISOPROXIL FUMARATE HOẶC TENOFOVIR ALAFENAMIDE

Abstract

Objectives: To investigate the change in qHBsAg in chronic HBV patients treated with tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). Methods: A descriptive cross-sectional study was conducted on chronic HBV outpatients treated with TDF 300mg or TAF 25mg at the Hepatitis clinic, Ho Chi Minh City University of Medicine and Pharmacy Hospital from January 2017 to December 2020. The qHBsAg change was evaluated in patients treated with TDF or TAF. Results: There were 250 patients included in this study, of which 160 patients (64%) were treated with TDF and 90 patients (36%) with TAF. The mean duration of treatment in the TDF group was 4.1 years and in the TAF group was 2.5 years. The mean baseline qHBsAg value in  TDF group (3.0 ± 0.8 (log10 UI/ml)) was significantly higher than that in TAF group (2.7 ± 0.9), p=0.02. In the TDF-treated group, the mean qHBsAg value at 12 weeks was not significantly different, compared to that at baseline (p = 0.2), but the qHBsAg decreased significantly at 24 weeks (p = 0.02). In the TAF-treated group, the mean qHBsAg value  was not significantly diferent at 12 weeks (p = 0.8) and 24 weeks (p = 0.4) compared to baseline one. Conclusion: The study showed that qHBsAg value decreased significantly at 24 weeks during TDF treatment. However, qHBsAg value did not decrease significantly during short-term TAF treatment. More studies with larger sample sizes, multicenters and longer follow-up are needed to evaluate the effectiveness of drugs in the change of qHBsAg.